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Abstract
Background: To discover cancer specific DNA methylation markers, large-scale screening methods are widely used. The
pharmacological unmasking expression microarray approach is an elegant method to enrich for genes that are silenced and re-
expressed during functional reversal of DNA methylation upon treatment with demethylation agents. However, such
experiments are performed in in vitro (cancer) cell lines, mostly with poor relevance when extrapolating to primary cancers. To
overcome this problem, we incorporated data from primary cancer samples in the experimental design. A strategy to combine
and rank data from these different data sources is essential to minimize the experimental work in the validation steps.
Aim: To apply a new relaxation ranking algorithm to enrich DNA methylation markers in cervical cancer.
Results: The application of a new sorting methodology allowed us to sort high-throughput microarray data from both cervical
cancer cell lines and primary cervical cancer samples. The performance of the sorting was analyzed in silico. Pathway and gene
ontology analysis was performed on the top-selection and gives a strong indication that the ranking methodology is able to enrich
towards genes that might be methylated. Terms like regulation of progression through cell cycle, positive regulation of
programmed cell death as well as organ development and embryonic development are overrepresented. Combined with the
highly enriched number of imprinted and X-chromosome located genes, and increased prevalence of known methylation
markers selected from cervical (the highest-ranking known gene is CCNA1) as well as from other cancer types, the use of the
ranking algorithm seems to be powerful in enriching towards methylated genes.
Verification of the DNA methylation state of the 10 highest-ranking genes revealed that 7/9 (78%) gene promoters showed DNA
methylation in cervical carcinomas. Of these 7 genes, 3 (SST, HTRA3 and NPTX1) are not methylated in normal cervix tissue.
Conclusion: The application of this new relaxation ranking methodology allowed us to significantly enrich towards methylation
genes in cancer. This enrichment is both shown in silico and by experimental validation, and revealed novel methylation markers
as proof-of-concept that might be useful in early cancer detection in cervical scrapings.
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Background
DNA methylation represents a modification of DNA by
addition of a methyl group to a cytosine, also referred to
as the fifth base [1]. This epigenetic change does not alter
the primary DNA sequence and might contribute to over-
all genetic stability and maintenance of chromosomal
integrity. Consequently, it facilitates the organization of
the genome into active and inactive regions with respect
to gene transcription [2]. Genes with CpG islands in the
promoter region are generally unmethylated in normal
tissues. Upon DNA hypermethylation, transcription of
the affected genes may be blocked, resulting in gene
silencing. In neoplasia, hypermethylation is now consid-
ered as one of the important mechanisms resulting in
silencing expression of tumour suppressor genes, i.e.
genes responsible for control of normal cell differentia-
tion and/or inhibition of cell growth [3]. In many cancers,
various markers have been reported to be hypermethyl-
ated [4]. The detection of DNA hypermethylation was rev-
olutionized by two discoveries. Bisulfite treatment results
in the conversion of cytosine residues into uracil, except
the protected methylcytosine residues [5]. Based on the
sequence differences after bisulfite treatment, methylated
DNA can be distinguished from unmethylated DNA,
using methylation specific PCR (MSP) [6].
In the last few years, hypermethylated biomarkers have
been used in cancer research and diagnostics [7-9]. Pres-
ently, DNA hypermethylation of only few markers is of
clinical relevance [9]. Two classical examples are hyper-
methylation of MGMT  in the prediction of treatment
response to temozolomide in glioblastoma [10] and DNA
hypermethylation of GSTP1 in the early detection of pros-
tate cancer [11]. The search for markers that are hyper-
methylated in specific cancer types resulted in a large list
of genes but more recent evidence revealed that many of
these markers are methylated in normal tissues as well
[12,13].
To discover novel markers that are specific for certain
stages of cancer with a high specificity and sensitivity,
large-scale screening methods were developed such as
Restriction Landmark Genomic Scanning [14], Differen-
tial Methylation Hybridization [15-17], Illumina Golden-
Gate® Methylation, microarray-based Integrated Analysis
of Methylation by Isoschizomers (MIAMI) [18] and
MeDIP [19] in combination with methylation-specific oli-
gonucleotide microarray [20]. These approaches demon-
strated that large-scale screening techniques have a large
potential to find novel methylation targets in a whole
range of cancers. To identify cancer related hypermethyl-
ated genes, also pharmacological unmasking expression
microarray approaches were suited [21-23]. In this
approach, the re-activation of gene expression using
microarray analysis was studied during functional reversal
of DNA methylation and histone acetylation in cancer cell
lines using demethylating agents and histone deacetylase
inhibitors. This methodology generally results in a list of
several hundreds of candidate genes. Although the analy-
sis of the promoter (e.g. screening for dense CpG islands)
is used to narrow down the number of candidate genes,
the number list is still too large. This methodology has
proven relevant as its application resulted in the identifi-
cation of new potential methylated genes [24,25].
However, the initial large scale screening approach will
also detect many genes that are not directly methylation
targets themselves but become re-activated due to the re-
expression of for instance transcription factors [26]. Fur-
thermore, in most studies only re-expression data after
demethylation in cell lines were used. Smiraglia and co-
workers [27] calculated that more than 57% of the loci
methylated in cell lines were never methylated in 114 pri-
mary cancers of different malignancy types. The small
number of cell lines used to identify methylated genes
does not allow to draw conclusions on the relevance of
such cancer-specific genes without testing a large series of
primary tumours, which is not done in most studies.
Finally, the completion of the sequence of the human
genome provided information on genes, promoter gene
structure, CG-content and chromosomal localization.
These data are useful to define criteria for the candidate
genes to act as appropriate targets for DNA methylation.
To identify genes that are downregulated due to promoter
hypermethylation and to enrich for those genes that are
most frequently involved in cervical cancer, we performed
the following experiments:
￿ Affymetrix expression microarray analysis on a panel of
frozen tissue samples from 39 human primary cervical
cancers to identify cancer specific down-regulated genes
￿ To select those genes that are hypermethylated in cervi-
cal cancer, Affymetrix expression microarray analysis on a
panel of 4 different cervical cancer cell lines in which the
expression of (hyper)methylated genes was re-activated
upon treatment with 5-aza-2'deoxycytidine (DAC)
(blocking DNA methylation), and/or trichostatin A (TSA)
(inhibiting histone deacetylase (HDACi))
￿ Data from both approaches were combined, and a novel
non-parametrical ranking and selection method was
applied to identify and rank candidate genes. Using in sil-
ico promoter analysis we restricted the analysis to those
candidate genes that carry CpG islands
To validate whether our new approach resulted in a signif-
icant enrichment of hypermethylated genes, we comparedBMC Medical Genomics 2008, 1:57 http://www.biomedcentral.com/1755-8794/1/57
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the first 3000 high-ranking candidate probes with lists of
imprinted genes, X-chromosome located genes and
known methylation markers. In addition, to investigate
whether the promoters of these selected gene probes are
hypermethylated and this methylation is present in cancer
and not in normal tissue, we determined the hypermeth-
ylation status of the 10 highest ranking candidate genes in
both cervical cancers and normal cervices using COBRA
(COmbined Bisulfite Restriction Analysis). These data
revealed a highly significant enrichment of methylated
genes.
Methods
Primary cervical tissue samples
For the expression microarray analysis, tissues from 39
early stage frozen cervical cancer samples were used from
a collection of primary tumours surgically removed
between 1993 and 2003. All patients were asked to partic-
ipate in our study during their initial visit to the outpa-
tient clinic of the University Medical Centre Groningen
(UMCG, Groningen, The Netherlands). Gynaecological
examination under general anaesthesia was performed in
all cervical cancer patients for staging in accordance with
the International Federation of Gynaecology and Obstet-
rics (FIGO) criteria [28]. Tumour samples were collected
after surgery and stored at -80°C. The stage of cervical can-
cer patients included 33 FIGO stage IB (85%) and 6 FIGO
stage IIA (15%). The median age of the cervical cancer
patients was 46 years (IQ range 35 – 52 yr.).
For COBRA and BSP (Bisulfite Sequencing PCR), 10 (of
the 39) primary cervical cancers and 5 controls (normal
cervix) were used. The age-matched normal cervical con-
trols were women without a history of abnormal Pap
smears or any form of cancer and planned to undergo a
hysterectomy for benign reasons during the same period.
Normal cervices were collected after surgery and histolog-
ically confirmed.
Informed consent was obtained from all patients partici-
pating in this study. The study was approved by the ethics
committee of the UMCG.
Cervical cancer cell lines
Four cervical carcinoma cell lines were used: HeLa (cervi-
cal adenocarcinoma, HPV18), SiHa (cervical squamous
cell carcinoma, HPV16), CSCC-7 (nonkeratinizing large
cell cervical squamous cell carcinoma, HPV16) and CC-8
(cervical adenosquamous carcinoma, HPV45). HeLa and
SiHa were obtained from the American Tissue Type Col-
lection. CSCC-7 and CC-8 [29] were a kind gift of Prof. GJ
Fleuren (Leiden University Medical Centre, Leiden, the
Netherlands). All cell lines were cultured in DMEM/
Ham's F12 supplemented with 10% fetal calf serum.
Cell lines were treated for 3 days with low to high dose
(200 nM, 1 μM or 5 μM) 5-aza-2'deoxycytidine (DAC),
200 nM DAC with 300 nM trichostatin A (TSA) after 48
hours, or left untreated as described previously
[21,23,30]. Cells were split to low density 24 hours before
treatment. Every 24 hours DAC was refreshed. After 72
hours cells were collected for RNA isolation.
RNA and DNA isolation
From the frozen biopsies, four 10-μm-thick sections were
cut and used for standard RNA and DNA isolation. After
cutting, a 3-μm-thick section was stained with haematox-
ylin/eosin for histological examination and only tissues
with >80% tumour cells were included. Macrodissection
was performed to enrich for epithelial cells in all normal
cervices.
For DNA isolation, cells and tissue sections were dissolved
in lysis buffer and incubated overnight at 55°C. DNA was
extracted using standard salt-chloroform extraction and
ethanol precipitation for high molecular DNA and dis-
solved in 250 μl TE-4 buffer (10 mM Tris; 1 mM EDTA
(pH 8.0)). For quality control, genomic DNA was ampli-
fied in a multiplex PCR containing a control gene primer
set resulting in products of 100, 200, 300, 400 and 600 bp
according to the BIOMED-2 protocol [31].
RNA was isolated with TRIzol reagent (Invitrogen, Breda,
the Netherlands) according to manufacturer's protocol.
RNA was treated with DNAse and purified using the RNe-
asy mini-kit (Qiagen, Westburg, Leusden, the Nether-
lands). The quality and quantity of the RNA was
determined by Agilent Lab-on-Chip analysis (ServiceXS,
Leiden, the Netherlands, http://www.serviceXS.com.
Expression data
Gene expression for 39 primary cancers and 20 cell line
samples (4 cell lines treated with various combinations of
DAC/TSA) was performed using the Affymetrix HGU 133
Plus 2.0 array with 54,675 probes for analysis of over
47,000 human transcripts. The labelling of the RNA, the
quality control, the microarray hybridization and scan-
ning were performed by ServiceXS according to Affymetrix
standards. For labelling, 10 μg of total RNA was amplified
by in vitro transcription using T7 RNA polymerase.
Quality of the microarray data was checked using histo-
grams, box plots and a RNA degradation plot. One cell
line sample was omitted because of poor quality. Using
BioConductor [32] present (P), absent (A) or marginal
(M) calls were determined with the MAS5 algorithm (see
Additional file 1 for data). MAS5 uses a non-parametric
statistical test (Wilcoxon signed rank test) that assesses
whether significantly more perfect matches show more
hybridization signal than their corresponding mis-BMC Medical Genomics 2008, 1:57 http://www.biomedcentral.com/1755-8794/1/57
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matches to produce the detection call for each probe set
[33]. The relaxation ranking approach only relied on P-
calls. Some samples were analyzed in duplicate, and the
profile of P-calls is highly similar (93–95% of the
probesets have an identical P/M/A call).
Relaxation ranking algorithm
In order to identify the most promising markers that are
methylated in cervical cancer, we assumed that such mark-
ers should be silenced in cancer cells and upregulated
upon re-activation after DAC/TSA treatment, Therefore,
the ideal methylation markers will be genes represented
by probes with:
￿ no expression in primary cervical cancers: P-calls = 0 out
of 39 cancers
￿ no expression in (untreated) cervical cancer cell lines: P-
calls = 0 out of 4 cell lines
￿ expression in cervical cancer cell lines treated with DAC
(or DAC in combination with TSA): P-calls = 15 out of 15
treated cell lines
To select for those gene probes that would be the best can-
didate hypermethylated genes in cervical cancer, we
present the relaxation ranking algorithm. Probesets were
ranked, not primarily based on the number of P-calls and
thus explicitly setting thresholds, but primarily driven by
the number of probesets that would be picked up, based
on selection criteria (the number of P-calls in primary can-
cers, untreated and treated cell lines). The stricter (e.g. P-
calls: 0-0-15) these selection criteria, the lower the
number of probes that meet with these criteria; while if
the conditions become more and more relaxed (higher
number of P-calls in primary cancers and untreated cell
lines, and lower number of P-calls in treated cell lines),
the more probes will comply. In the end, using P-calls: 39-
4-0 as criteria, all probe sets were returned. This way, there
was no need to define a 'prior' threshold for the number
of P-calls.
The following sorting method was applied (R-scripts are
presented in Additional file 2):
(1) All possible conditions were generated and the
number of probes that were picked up under these condi-
tions was calculated:
a. the number of samples with expression (P) of a certain
probe in
i. primary cervical cancer samples is called xsample
ii. cervical cancer cell lines is called ysample
iii. treated cervical cancer cell lines is called zsample
b. all combinations of x, y and z are made
i. x (the number of P-calls in primary cancers) varies from
0 to 39
ii. y (the number of P-calls in untreated cell lines) from 0
to 4
iii. z (the number of P-calls in treated cell lines) from 0 to
15
iv. In total, 3200 combinations of x, y and z can be made
c. a probeset was found under each of these generated
conditions x, y and z if:
i. xsample ≤ x (number of P-calls for probe in primary can-
cers smaller or equal compared to condition) AND
ii. ysample ≤ y (number of P-calls for probe in untreated cell
lines smaller or equal compared to condition) AND
iii. zsample ≥ z (number of P-calls for probe in treated cell
lines larger or equal compared to condition)
d. under very strict conditions (x = 0, y = 0, z = 15) no
probes were found, while under the most relaxed condi-
tions (x = 39, y = 4, z = 0) all probes were returned. For all
combinations of x, y and z, the number of probes that
complied (w), was stored
(2) The data was sorted with w as primary criterion
(ascending), followed by x (ascending), y (ascending) and
z (descending)
(3) This sorted dataset was analyzed row per row. In row
i, the wi probes retrieved with criteria xi yi zi were com-
pared with the list of probes, already picked up in rows 1
to i-1. If a probe did not occur in this list, it was added to
the list
(4) This process continued until there were m (user-
defined) probes in the list
All in silico statistical enrichment tests are chi-square tests
with Yates' correction, given p values are two-tailed.
DNA methylation analysis using COBRA and bisulfite 
sequencing (BSP)
To validate the (hyper)methylation status of candidate
gene probes, DNA extracted from 10 cervical cancers and
5 normal cervices were analyzed using BSP and COBRA.
Bisulfite modification of genomic DNA was performedBMC Medical Genomics 2008, 1:57 http://www.biomedcentral.com/1755-8794/1/57
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using the EZ DNA methylation kit (Zymogen, BaseClear,
Leiden, the Netherlands). The 5' promoter region of the
tested gene was amplified using bisulfite treated DNA.
PCR primers for amplification of specific targets
sequences are listed in Additional file 3. COBRA was per-
formed directly on the BSP products as described by Xiong
et al. [34]. using digestions with BstUI, Taq1 and/or HinfI
according the manufacture's protocol (New England
Biolabs Inc., Beverly, MA). For sequence analysis, the BSP
products were purified (Qiagen, Westburg, Leusden, the
Netherlands) and subjected to direct sequencing (Base-
Clear, Leiden, the Netherlands). Leukocyte DNA collected
from anonymous healthy volunteers and in vitro CpG
methylated DNA with SssI (CpG) methyltransferase (New
England Biolabs Inc., Beverly, MA) were used as negative
and positive control, respectively.
Results
To identify novel markers that are methylated in cervical
cancer, we applied a multistep approach that combines re-
expression of silenced hypermethylated genes in cervical
cancer cell lines (using DAC and DAC/TSA), downregu-
lated expression in 39 cervical cancers expression, and
selection of candidate markers using a relaxing ranking
algorithm. The best profile of a candidate marker would
be: no expression in any of the 39 cervical primary cancers
and 4 untreated cancer cell lines, but re-activation of
expression after demethylation and/or blocking of his-
tone deacetylation in all 15 cell lines treated with various
combinations of DAC/TSA (P-calls: 0-0-15). However,
none of the probe sets showed this ideal profile. To gener-
ate a list of candidate genes, a relaxation ranking algo-
rithm was applied.
The only variable used in the relaxation ranking is the
number of probes we would like to retrieve. As shown in
Figure 1, the number of probes retrieved (w) with param-
eters x, y and z (the number of P-calls in respectively pri-
mary tumour samples, untreated and treated cell lines)
follows a complex profile which consists not only of addi-
tive elements, but also interactions between the parame-
ters. In general, the number of P-calls in primary cancer
samples (x) has the largest influence on w. The sorting
methodology has the advantage that no cut-off values
have to be chosen for x, y and z, and therefore there is no
need to implicitly link a relative weight factor to the
parameters.
To calculate the most optimal number of potentially
hypermethylated candidate markers for further analysis,
we estimated this number based on known (i.e. described
in literature) methylation markers in cervical cancer.
Forty-five known methylation markers were found using
text-mining using GeneCards [35] as source of aliases/
symbols to query PubMed through NCBI E-Utils (Addi-
tional file 4). The position of the markers after ranking
("observed") was determined as shown in the step plot in
Figure 2. If the markers would be randomly distributed in
the ranking, the profile would be similar to the curve,
marked 'expected'. This 'expected' curve is not a straight
line, but is calculated based on whether a probe could be
assigned with a gene symbol and taking probes into
account that are associated with a gene that was already
associated with an earlier selected probe. The number of
observed methylation markers has in general the same
slope as expected. However, up to about 3000 probes, the
slope of the number observed markers versus the number
of selected probes (in dashed lines) cannot be explained if
the markers would be randomly distributed as its steep-
ness is much higher. When selecting more than 3000
probes, the slope suddenly decreases to a level that is close
to random distribution. This enrichment can also statisti-
cally be proven (see further). Therefore, we selected the
first 3000 probes, referred to as TOP3000, in the ranking
for further analysis. In this TOP3000 list, 2135 probes are
associated with a gene symbol, of which 1904 are unique.
The number of probes (w) that is retrieved using parameters x (number of P-calls in primary cancers for probe), y (number of  P-calls in untreated cell-lines for probe) and z (number of P-calls in treated cell-lines for probe) Figure 1
The number of probes (w) that is retrieved using parameters x (number of P-calls in primary cancers for 
probe), y (number of P-calls in untreated cell-lines for probe) and z (number of P-calls in treated cell-lines for 
probe).
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The validation of the TOP3000 probe-list selected using 
relaxing high-ranking
To validate whether the TOP3000 contains potential
hypermethylated genes, we determined the occurrence of
various gene sets that are known to be hypermethylated
such as imprinted genes, chromosome-X genes, cervical
cancer related hypermethylated genes and genes reported
to be methylated frequently in cancers, other than cervical
cancer.
A. Enrichment for imprinted genes
Imprinting is a genetic mechanism by which genes are
selectively expressed from the maternal or paternal homo-
logue of a chromosome. As methylation is one of the reg-
ulatory mechanisms controlling the allele-specific
expression of imprinted genes [36-40], it is expected that
known imprinted genes are enriched in the TOP3000
selection. According to the Imprinted Gene Catalogue
[41], this TOP3000 list contains 16 imprinted (or parent-
specific expressed) genes (Additional file 5). On the whole
Affymetrix array in total 74 imprinted genes could be
assigned with a probe. Taking into account duplicate
probes and probes that are not associated with a gene
symbol, 8.76 imprinted genes could be expected in the
first 3000 probes if the imprinted genes were randomly
distributed indicating a 1.83-fold [16/8.76] enrichment in
the TOP3000 (X2 = 5.904; p = 0.0151). The enrichment
towards imprinted genes is even more significant in the
TOP100 candidate genes (3 versus only 0.31 expected; X2
= 14.9; p < 0.0001).
Step-plot to determine optimal number of probes for further analysis Figure 2
Step-plot to determine optimal number of probes for further analysis. Step-plot of the number of retrieved known 
markers (45 published hypermethylation markers in cervical cancer, see Additional file 4) as a function of the position after 
relaxation ranking (this is the number of selected probes after ranking). The step plot shows the actual (observed) number of 
markers. If the markers were randomly distributed, one would expect the profile, marked with 'expected' (details in the text). 
The trend of the observed markers versus the number of selected probes is indicated with dashed lines.
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B. Enrichment for genes on the X-chromosome
X-chromosome-inactivation in females is initiated from
an inactivation centre that produces the Xist transcript, an
RNA molecule that covers one copy of the X-chromosome
and results in silencing of gene expression. This coating
initiates a number of chromatin changes including stable
DNA methylation [42]. Of the entire list of 54675 probes
on this Affymetrix array, 40683 could be associated with a
chromosomal location, 1325 probes are located on the X-
chromosome. In the TOP3000 list (with 2239 chromo-
somal locations known), 93 probes are located on chro-
mosome X (data not shown) indicating a significant
enrichment (1.28-fold) of X-chromosome-located probes
in the TOP3000 (X2 = 5.8; p = 0.0165). This enrichment is
even more significant within the TOP1000 (42/708 chro-
mosomal locations; X2 = 12.567; p = 0.0004) and TOP100
probes (13/71 chromosomal regions known; X2 = 36.097;
p < 0.0001).
C. Enrichment for cervical cancer specific methylation markers
The enrichment of known methylation markers involved
in cervical cancer (Additional file 4) was already illus-
trated significant when calculating the optimal number of
probes for further testing (see Figure 2), and hereby dem-
onstrated the enrichment towards these markers. In the
TOP3000, 10 known genes are present (Table 1). As only
5.33 probes of these known methylation markers for cer-
vical cancer are expected if randomly distributed, the
TOP3000 list is enriched for these markers 1.88-fold (X2 =
3.715 ; p = 0.0539).
D. Enrichment for known hypermethylation markers in cancers other 
than cervical cancer
To determine whether the ranking methodology is able to
enrich towards known hypermethylation markers
reported in various cancer types, PubMeth (a literature-
based methylation database) was used [43]. Of the 40683
gene-probes on the Affymetrix array, 349 genes are
present in the database. Interestingly, in the TOP250
probes (representing 152 unique genes), 10 known meth-
ylation are described in the database (see table 2). If ran-
domly distributed, taking duplicate probes and probes
not associated with gene symbols into account, 3.3 genes
were expected (X2 = 12.028, p = 0.0005). This enrichment
is also observed in the TOP1000 (27 known markers vs.
14 expected, X2 = 11.947, p = 0.0005) and TOP3000
probes (55 known markers vs. 41 expected, X2 = 4.871, p
= 0.0273).
Interestingly, this analysis revealed that in the TOP-250
known methylation markers seem to be significantly
enriched and highly-ranked. This also showed that the
known cervical cancer-specific markers are not enriched to
the same extend (CCNA1  is highest at position 234),
implying the existence of better hypermethylated markers,
involved in cervical cancer, in the TOP3000 list.
In summary, as the top-list contains a relatively large
number of imprinted, chromosome-X and known meth-
ylation markers, our analysis revealed that the ranking
strategy was able to enrich the candidate gene list with
possible new (hyper)methylated genes.
E. Gene Ontology
Associated with the development and progression of can-
cer, silencing by hypermethylation often affects genes in
important pathways [44]. Therefore, we investigated
whether our selected TOP3000 candidate genes are asso-
ciated with specific pathways or harbour related func-
tions. Multiple GO-terms using Gene Ontology (GO) by
GOstat [45] (Additional file 6) and specific pathways
using Ingenuity Pathway Analysis (IPA) (Additional file
7), were significantly over-represented within the
TOP3000 list when compared to all annotated human
genes.
These terms include regulation of transcription – DNA-
dependent, transcription from RNA polymerase II pro-
moter, regulation of progression through cell cycle, posi-
tive regulation of programmed cell death as well as organ
Table 1: Reported DNA methylation markers in cervical cancer present in the TOP3000
Gene symbol Rank Profile X-Y-Z Chromosomal location References
CCNA1 234 3-0-7 13q12.3-q13 [48]
TIMP2 404 20-3-14 17q25 [62]
TFPI2 651 12-0-7 7q22 [22]
PEG3 1242 10-0-6 19q13.4 [63]
RUNX3 1463 39-3-15 1p36 [64]
IGSF4 1742 38-0-7 11q23.2 [65]
PTEN 1926 15-1-8 10q23.3 [66]
TNFRSF10D 2270 30-4-15 8p21 [67]
TIMP3 2500 32-3-13 22q12.3 [13]
APC 2733 11-0-5 5q21-q22 [13]
Published DNA methylation markers in cervical cancer were selected by literature text mining (see Additional file 4)BMC Medical Genomics 2008, 1:57 http://www.biomedcentral.com/1755-8794/1/57
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development and embryonic development (all p-values <
10-6 ; corrected for multiple hypothesis testing [46]).
Genes in these processes were reported to be often meth-
ylated during cancer progression [8]. Genes responsible
for development and differentiation are mainly silenced
by methylation in normal tissues. On the other hand, in
cancer tissues, genes responsible for cell cycle control and
induction of apoptosis are often aberrantly expressed as
many of these genes have tumour suppressor activity.
DNA hypermethylation is one mechanism to regulate
expression of tumour suppressor genes [47].
The GO-analysis provided additional strong indication
that our highest ranking genes in the top-list are signifi-
cantly enriched for methylated genes involved in cervical
cancer tissue or cell lines.
Validation of the 10 highest-ranking candidate genes using 
COBRA
In order to validate whether the highest ranking genes rep-
resent markers that are functionally hypermethylated in
cervical cancer, we performed COBRA on bisulfite treated
DNA of 10 cervical cancers and 5 normal cervices. For this
analysis, we focused on those first 10 genes from the high-
est ranking probe-list (Table 3) that (see Additional file 8
for more details):
￿ represent a known gene (i.e. gene symbol)
￿ contain a CpG island surrounding the TSS
Table 2: Listing of cancer associated hypermethylation markers that have been reported previously within the 250 highest ranking 
genes, as found by literature search (trough NCBI E-fetch, using GeneCards to search aliases)
Gene symbol Rank Profile X-Y-Z Chromosomal location References
ZIK1 6 16-1-15 19q13.43 Intestinal metaplasia
[68]
NNAT 1,2 21 0-1-11 20q11.2-q12 Pediatric acute leukemia
[40]
SST1 22 1-1-12 3q28 Colon cancer
[53]
SSX23 27 0-0-8 Xp11.23-p11.22 Bladder cancer
[69]
NPTX11 29 2-3-14 17q25.1-q25.2 Pancreatic cancer
[54]
PRSS21 72 18-3-15 16p13.3 Testicular cancer
[70,71]
CYP1A11 76 0-0-7 15q22-q24 Prostate cancer
[72]
MAGEA31,3 96 4-2-12 Xq28 Different cancer cell lines (Leukemic, Hepatic, Prostate, Breast, Colon)
[73]
Hepatocellular carcinoma
[74]
Melanoma
[75]
INSR 124 7-0-9 19p13.3-p13.2 Prostate cancer
[50]
DLX1 150 2-3-12 2q32 Lung cancer
[76]
PAX9 207 25-1-12 14q12-q13 Lung cancer
[76]
ZNF342 228 0-0-6 19q13.32 Brain cancer
[77]
CCNA11,4 234 3-0-7 13q12.3-q13 Cervical cancer
[48]
Head-and neck cancer
[30]
Oral cancer
[52]
CTCFL 245 14-0-9 20q13.31 Prostate and bladder cancer
[78]
LIFR 248 32-3-15 5p13-p12 Hepatocellular carcinoma
[79]
1Genes, whose promoter has been described in literature as being methylated in certain cancer types selected by screening the PubMeth database. 
2Imprinted. 3Located on the X-chromosome. 4Methylated in cervical cancer (literature search)BMC Medical Genomics 2008, 1:57 http://www.biomedcentral.com/1755-8794/1/57
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￿ are located on any chromosome except chromosome X
￿ are expressed (present) in less than 15 carcinomas, in
order to identify markers to be methylated in ≥60% of cer-
vical cancers (no P-call)
BSP was used to amplify the CpG islands of these candi-
date genes using bisulfite-treated DNA and COBRA to
determine the methylation status. CCNA1 (at position 49;
Additional file 8) was included as a positive control for
the highest listed, reported cervical cancer specific methyl-
ation gene promoter. COBRA of CCNA1 revealed that 6 of
10 carcinomas are methylated at the restriction enzyme
sites (T1, T3, T5, T7, T9 and T10 in Figure 3). Sequence
analysis of the BSP products (on average 7–9 independent
clones for each carcinoma) of these 10 carcinomas
revealed that in 6 carcinomas the promoter is hypermeth-
ylated in good agreement with the COBRA results (Figure
3C).
Table 3 summarizes the methylation status of the 10 high-
est ranking genes in 10 cervical cancer and 5 normal cer-
vices using COBRA. One gene (ADARB1 at rank 2) could
not be analyzed for methylation as no specific BSP prod-
ucts could be amplified using several combinations of
primer pairs. Interestingly, using the BSP products of the
other 9 listed genes, 7 (78%) showed methylation in car-
cinomas (Table 3).
Four genes are hypermethylated in all 9 tested cancers,
while for SST (7 of 9 carcinomas), HTRA3 (1 of 9 carcino-
mas) and NPTX1 (5 of 10 carcinomas) a fraction of the
tested carcinomas is hypermethylated. Figure 4 shows a
representative methylation analysis of 3 genes using
COBRA. Three (NNAT, SST and NPTX1) of the 7 hyper-
methylated gene promoters have been reported to be
methylated in tumours previously (see Table 2). Taken
these data together, these findings showed that the relaxa-
tion ranking algorithm resulted in a very significant
enrichment towards genes with a positive methylation
status.
Enrichment of cervical cancer specific methylation 
markers
A cancer specific cervix hypermethylation marker is only
of relevance for the diagnosis of (pre-) malignant disease
in case normal cervical epithelium is not methylated.
COBRA analysis of 5 normal cervices for all 9 genes
revealed that 4 genes (DAZL,SYCP3,ZFP42 and NNAT) are
hypermethylated in all 5 samples (Table 3).
On the other hand, of the 7 genes hypermethylated in cer-
vical cancer specimens, 3 genes (SST, HTRA3 and NPTX1)
did not show DNA methylation in any of the normal cer-
vices of 5 independent individuals. We observed the same
methylation profile for CCNA1 that was reported previ-
ously as a cervical cancer specific gene [48] with hyper-
methylation in only 6 of 10 tumours but none of the 5
normals (Table 3). This analysis revealed that the relaxa-
tion ranking algorithm not only resulted in a very signifi-
cant enrichment for genes with a positive methylation
status, but also for hypermethylated genes that are specif-
ically methylated in cancers and not in the normal cervi-
ces.
Discussion and conclusion
In this study, we optimized the identification of methyla-
tion markers after pharmacological unmasking microar-
ray approach combined with microarray expression data
of primary cancer samples. For the integration of data
from both cell lines and primary cancers, we developed a
novel ranking strategy, which combines re-activation in
cell lines and no expression in primary cancer tissue. The
relaxation ranking algorithm uses a non-parametrical
Table 3: Methylation status using COBRA of the 10 highest-ranking gene promoters.
Rank Gene symbol Profile X-Y-Z Chromosomal location Methylation in cancer Methylation in normal
1 DAZL 1-1-13 3p24.3 9/9 5/5
2 ADARB1 1-2-15 21q22.3 Nd Nd
3 SYCP3 0-1-12 12q 9/9 5/5
4 AUTS2 12-0-12 7q11.22 0/9 0/5
5 NNAT 0-1-11 20q11.2 9/9 5/5
6 SST 1-1-12 3q28 7/9 0/5
7 HTRA3 6-0-10 4p16.1 1/9 0/5
8 ZFP42 11-1-14 4q35.2 9/9 5/5
9 NPTX1 2-3-14 17q25.1 5/10 0/5
10 GDA 14-3-15 9q21.13 0/9 0/5
47 CCNA1 3-0-7 13q12.3-q13 6/10 0/5
Gene, selected for further validation after applying additional criteria. Included is CCNA1 on position 47 (original position 241) as the highest 
ranking cervical-cancer-associated hypermethylated gene (see Table 2). Methylation status was determined by BSP/COBRA (see Figure 3 and 
Figure 4).BMC Medical Genomics 2008, 1:57 http://www.biomedcentral.com/1755-8794/1/57
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method of sorting. No threshold on expression level or P-
calls has to be set and no overlap between different cell
lines has to be chosen. The only parameter needed is the
number of probes/genes that should be included in the
top list. Using this algorithm, genes can still be selected
for further analysis, even if it is not in (almost) all cell
lines re-expressed or not silenced in most primary tumour
samples.
In this study, we showed that the experimental design in
combination with the ranking strategy is able to enrich a
list of probes for methylated genes. Imprinted genes and
genes on the X-chromosome are significantly enriched in
the high-ranking TOP3000 probes. Pathway and gene
ontology analysis illustrates that the high-ranking genes
are involved in tumour development and progression.
Enrichment of similar pathways or ontologies when
selecting abnormal expressed genes is commonly reported
in various cancer types [49,50]. More importantly, meth-
ylation markers reported to be involved in various cancers
(including cervical cancer) are significantly enriched in
the top-lists as well. Interestingly, the highest ranking cer-
vical cancer specific gene is CCNA1 (position 234 in Addi-
tional file 8; position 47 in Table 3). Apart from cervical
cancer, CCNA1 was reported to be hypermethylated in
colorectal, oral and head and neck cancer [30,51,52]. In
good agreement with the reported data, we show that
CCNA1 is hypermethylated in 6 of 10 cervical carcinomas
and none of the normal cervices using COBRA and BSP
sequencing (Table 3 and Figure 3).
(Hyper)methylation analysis of the promoter region (-430 to -5 of TSS) of the CCNA1 gene by COBRA and sequence analysis Figure 3
(Hyper)methylation analysis of the promoter region (-430 to -5 of TSS) of the CCNA1 gene by COBRA and 
sequence analysis. A: schematic representation of the restriction enzyme sites (B: BstUI and T: TaqI) in the virtual hyper-
methylated BSP nucleotide sequence after bisulfite treatment. Vertical bars represent CG site, arrow represents TSS 
(retrieved from Ensembl). B: Result of COBRA analysis of the BSP products of 10 tumour samples (T1-T10), in vitro methyl-
ated DNA as a positive control (IV) and leucocyte DNA as a negative (unmethylated) control (L). C. Schematic representation 
of the sequencing results. From each tumour, the BSP-products were cloned into TOPO-pCR4 (Invitrogen) and sequencing 
(BaseClear) was performed on M13-PCR products of 7–9 independent clones. Circles represent CG dinucleotides: the darker, 
the more clones at this site were methylated.
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Analysis of the methylation status of the highest ranking
genes revealed that seven out of nine selected genes (78%)
are methylated in cervical cancers, whereas 4 of these 7
genes (DAZL, SYCP3, ZFP42 and NNAT) were also hyper-
methylated in all 5 normal cervices (Table 3). Although
hypermethylation of NNAT has been implicated in paedi-
atric acute leukaemia [40], the hypermethylation status in
both cancer and normal tissues suggests that NNAT acts as
an imprinted gene (Additional file 5) rather than a cancer
specific methylation marker in cervical cancer. The other
three genes (SST, HTRA3 and NPTX1) might be cancer
specific because these genes are, similar as CCNA1, hyper-
methylated in the cancers and not in the normal controls
(Table 3). Of these genes, two were previously described
as cancer specific genes: SST in colon carcinoma [53] and
NPTX1 in pancreatic cancer [54]. However, all 3 genes
have not been described previously in cervical cancer. The
exact involvement in cervical cancer development of these
3 genes has to be explored in the future, but the applica-
tion of the relaxation ranking algorithm illustrates the
power of enrichment for new hypermethylated genes that
can discriminate between cervical cancer and normal cer-
vical epithelium.
The combination of the initial setup and the analysis is
unique. In most other studies either few genes are investi-
gated for their methylation status in primary cancer sam-
ples or a large-screening approach is applied on cell lines
only. Generally, only genes which are re-expressed in
most cell lines can be retained for further investigation, as
Representative COBRA on 3 gene promoters (SST, AUTS2 and SYCP3) Figure 4
Representative COBRA on 3 gene promoters (SST, AUTS2 and SYCP3). A: schematic representation of of the restric-
tion enzyme sites in the virtual hypermethylated BSP nucleotide sequence after bisulfite treatment.(B: BstUI, T: TaqI and H: 
HinfI). Bars represent CG site and arrow is TSS (retrieved from Ensembl). B: Result of COBRA analysis of BSP products of 
tumour samples (T1-T10) and 5 normal cervices (N1-N5), in vitro methylated DNA as a positive control (IV) and leukocyte 
DNA as a negative (unmethylated) control (L); lane B is water blank.
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several hundreds of genes are upregulated in one or more
cell lines after treatment with DAC/TSA. Most studies used
additional filtering (such as pathway analysis, known
mutated genes), but the list of candidate genes that need
experimental validation to determine their methylation
status is long. These markers need to go through a pipeline
of DNA methylation detection in cell lines and cancer
samples, in order to find only a few cancer specific mark-
ers with different sensitivity and specificity [21,23,53].
However, the success rate is relatively low, as many pro-
moter regions do not show (differential) methylation. In
addition, CpG arrays can be used to identify putative
methylation markers, as recently described for cervical
cancer [55]. Again, this method requires the analysis of
many markers to end up with only few cervical cancer spe-
cific methylation markers.
In the last few years it became apparent that many markers
that are methylated in cancer have been shown to be
methylated in normal tissues as well [12,13,56,57]. Our
present analysis once more illustrates that many more
genes, preceded by a CpG island in the promoter region,
are methylated in normal tissue as well than was previ-
ously anticipated. To be able to further increase the
enrichment for these cancer specific methylated markers,
the inclusion of expression microarray data from normal
tissue in the relaxation ranking algorithm analysis might
be helpful. To validate this, we performed global gene
expression microarray analysis using the Affymetrix HGU
133 Plus 2.0 array with 54,675 probes (in parallel with the
samples described in this study) on 5 independent age-
matched normal cervices from healthy women. We
assume that cancer specific methylated markers should be
expressed in all normal cervices resulting in a positive P-
call (most optimal P-call = 5). Including the P-call for nor-
mal expression on our 10 highest ranked methylated
genes and CCNA1 (as listed in Table 3), revealed that all
the four cervical cancer specific methylated genes (SST,
HTRA3,  NPTX1  and  CCNA1) would not have been
selected as none of the normal cervices showed a P-call for
these probes (data not shown). It is generally accepted
that tumor suppressor genes (including cancer specific
methylated genes) are characterized by the fact that their
expression can be downregulated as the result of methyl-
ation, mutations and/or deletions, but is still present in its
normal counterpart tissue. However, the expression levels
in normal tissue are relatively low for most of these genes
when compared to those cancer tissues that do not show
downregulation as was reported for p16INK4a [58]. Thus,
our data suggest that the addition of expression data of
normal cervices would not enrich for cervical cancer spe-
cific methylated genes.
Other possibilities to further refine the selection of cancer
relevant hypermethylated genes are to restrict the ranking
to gene promoters that are likely to be methylated because
of defined CG-content or the presence of conserved motifs
(or similar sequence attributes) related to hypermethyl-
ated promoters [59-61]. Recently, we identified novel
methylation markers, based on a genome-wide promoter
alignment [57]. Promoters, closely related in the align-
ment with known methylation markers show to have a
high chance to be methylated as well.
In conclusion, the application of this new relaxation rank-
ing methodology allowed us to significantly enrich
towards methylation genes in cancer. This enrichment is
both shown in silico and by experimental validation, and
revealed novel methylation markers as proof-of-concept
that might be useful in early cancer detection in cervical
scrapings.
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